Ceftolozane & Tazobactam
- TRADE NAME: Zerbaxa (Cubist)
- INDICATIONS: Various infections caused by susceptible organisms
- CLASS: Antibiotic, Antibiotic; beta-lactam, Antimicrobial, Cephalosporin, Cephalosporin; 5th generation
- HALF-LIFE: <3 hours
FDA APPROVAL DATE: 12/19/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric